Cargando…

Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review

BACKGROUND: Evidence remains contradictory regarding second-line therapy in patients with Kawasaki disease (KD) refractory to initial intravenous immunoglobulin (IVIg). The objective of this study aims to evaluate the efficacy and safety of three treatments [i.e. a second IVIg infusion, methylpredni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crayne, Courtney B., Mitchell, Chace, Beukelman, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882052/ https://www.ncbi.nlm.nih.gov/pubmed/31775898 http://dx.doi.org/10.1186/s12969-019-0380-z

Ejemplares similares

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort
por: Mitchell, Chace, et al.
Publicado: (2019)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy
por: Soltner, Elise, et al.
Publicado: (2009)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
por: Dionne, Audrey, et al.
Publicado: (2018)

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease
por: Zhang, Rui Long, et al.
Publicado: (2020)

DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease
por: Portman, Michael A, et al.
Publicado: (2013)

A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment
por: Kim, Ju Young, et al.
Publicado: (2014)

An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children
por: Conte, Cristiano, et al.
Publicado: (2023)

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis
por: Li, Zheng, et al.
Publicado: (2023)

Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease
por: Inoue, Takashi, et al.
Publicado: (2020)

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment
por: Chen, Zhen, et al.
Publicado: (2023)

Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
por: Eloseily, Esraa M. A., et al.
Publicado: (2019)

Infliximab as rescue therapy in refractory Kawasaki disease
por: Rodríguez-González, Moisés, et al.
Publicado: (2014)

Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease
por: Kitoh, Toshiyuki, et al.
Publicado: (2021)

Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
por: Wang, Zhouping, et al.
Publicado: (2020)

Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease
por: Yoon, Kyung Lim, et al.
Publicado: (2017)

Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge
por: de Magalhães, Cristina Medeiros Ribeiro, et al.
Publicado: (2012)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
por: Huang, Ying-Hsien, et al.
Publicado: (2019)

Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness
por: Niu, Man Man, et al.
Publicado: (2021)

Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort
por: Li, Yujie, et al.
Publicado: (2022)

Recurrent refractory Kawasaki disease
por: Costa Reis, P, et al.
Publicado: (2011)

Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis
por: Pan, Bo, et al.
Publicado: (2023)

IVIG for refractory dysphagia in Antisynthetase syndrome: A truth hard to swallow
por: Alnoukari, Mais, et al.
Publicado: (2022)

Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review
por: Pinto, Ashwin A., et al.
Publicado: (2023)

Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease
por: Li, Sung-Chou, et al.
Publicado: (2016)

The “Intermediate” CD14 + CD16 + monocyte subpopulation plays a role in IVIG responsiveness of children with Kawasaki disease
por: Kim, Yi Seul, et al.
Publicado: (2021)

PTX3 promotes IVIG resistance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway
por: Sun, Ye, et al.
Publicado: (2023)

Clinical characteristics and correlation analysis of IVIG resistance in children with kawasaki disease complicated with hip synovitis: case-control study
por: Wang, Jianjie, et al.
Publicado: (2023)

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment
por: Seo, Euri, et al.
Publicado: (2016)

Predicting Factors for Refractory Kawasaki Disease
por: Do, Young-Sun, et al.
Publicado: (2010)

High-density Genotyping of Immune Loci in Kawasaki Disease and IVIG Treatment Response in European-American Case-parent Trio Study
por: Shendre, Aditi, et al.
Publicado: (2014)

The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease
por: Samadli, Sama, et al.
Publicado: (2019)

The Associated of the Risk of IVIG Resistance in Kawasaki Disease with ZNF112 Gene and ZNF180 Gene in a Southern Chinese Population
por: Lu, Zhaojin, et al.
Publicado: (2022)

Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature
por: Crayne, Courtney B., et al.
Publicado: (2018)

Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease
por: Chan, Han, et al.
Publicado: (2019)

A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease
por: Takeshita, Seiichiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ufu70u0gpun5jfcqsdtaveu2js